{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:38:59Z","timestamp":1792661939995,"version":"4.5.0"},"reference-count":39,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/fewg4694","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T02:53:22Z","timestamp":1767754402000},"page":"9275-9289","source":"Crossref","is-referenced-by-count":0,"title":["Effects of neoadjuvant endocrine therapy on surgical prognosis and survival period in patients with high-risk localized prostate cancer"],"prefix":"10.62347","volume":"17","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z and Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 2022; 10: 811044.","journal-title":"Front Public Health"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"853623","DOI":"10.3389\/fendo.2022.853623","article-title":"Burden of prostate cancer in China, 1990-2019: findings from the 2019 global burden of disease study","volume":"13","author":"Wang","year":"2022","unstructured":"Wang F, Wang C, Xia H, Lin Y, Zhang D, Yin P and Yao S. Burden of prostate cancer in China, 1990-2019: findings from the 2019 global burden of disease study. Front Endocrinol (Lausanne) 2022; 13: 853623.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"215927","DOI":"10.1016\/j.canlet.2022.215927","article-title":"Prostate cancer treatment - China’s perspective","volume":"550","author":"Liu","year":"2022","unstructured":"Liu J, Dong L, Zhu Y, Dong B, Sha J, Zhu HH, Pan J and Xue W. Prostate cancer treatment - China’s perspective. Cancer Lett 2022; 550: 215927.","journal-title":"Cancer Lett"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized prostate cancer: definition and outcomes","volume":"17","author":"Sundi","year":"2014","unstructured":"Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM and Ross AE. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis 2014; 17: 57-63.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_279459","article-title":"Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions","volume":"40","author":"McKay","year":"2020","unstructured":"McKay RR, Feng FY, Wang AY, Wallis CJD and Moses KA. Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions. Am Soc Clin Oncol Educ Book 2020; 40: 1-12.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref5","unstructured":"Katz MH and McKiernan JM. High-risk, clinically localized prostate cancer: is monotherapy adequate? Rev Urol 2007; 9 Suppl 2: S19-27."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.eururo.2018.10.032","article-title":"Comparative effectiveness of radical prostatectomy versus external beam radiation therapy plus brachytherapy in patients with high-risk localized prostate cancer","volume":"75","author":"Berg","year":"2019","unstructured":"Berg S, Cole AP, Krimphove MJ, Nabi J, Marchese M, Lipsitz SR, Noldus J, Choueiri TK, Kibel AS and Trinh QD. Comparative effectiveness of radical prostatectomy versus external beam radiation therapy plus brachytherapy in patients with high-risk localized prostate cancer. Eur Urol 2019; 75: 552-555.","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/JU.0000000000002826","article-title":"The added value of baseline health-related quality of life in predicting survival in high-risk prostate cancer patients following radical prostatectomy","volume":"208","author":"Westhofen","year":"2022","unstructured":"Westhofen T, Buchner A, Kasivisvanathan V, Lennartz S, Schlenker B, Becker A, Stief CG and Kretschmer A. The added value of baseline health-related quality of life in predicting survival in high-risk prostate cancer patients following radical prostatectomy. J Urol 2022; 208: 1056-1054.","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.euo.2025.05.006","article-title":"Influence of concomitant androgen deprivation therapy and its duration for salvage radiation after radical prostatectomy: a systematic review and network meta-analysis according to published data","volume":"8","author":"QC","year":"2025","unstructured":"Le QC, Siech C, Hoeh B, Saad F, Preisser F, Tilki D, Graefen M, Maurer T, Kriegmair MC, Karakiewicz PI, Chun FKH, Mandel P and Wenzel M. Influence of concomitant androgen deprivation therapy and its duration for salvage radiation after radical prostatectomy: a systematic review and network meta-analysis according to published data. Eur Urol Oncol 2025; 8: 1406-1415.","journal-title":"Eur Urol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","unstructured":"Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F and Joniau S. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol 2021; 18: 739-762.","journal-title":"Nat Rev Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"906370","DOI":"10.3389\/fonc.2022.906370","article-title":"Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy: a systematic review and meta-analysis","volume":"12","author":"Ge","year":"2022","unstructured":"Ge Q, Xu H, Yue D, Fan Z, Chen Z, Xu J, Zhou Y, Zhang S, Xue J, Shen B and Wei Z. Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy: a systematic review and meta-analysis. Front Oncol 2022; 12: 906370.","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/iju.14303","article-title":"Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer","volume":"27","author":"Van Poppel","year":"2020","unstructured":"Van Poppel H and Abrahamsson PA. Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. Int J Urol 2020; 27: 830-837.","journal-title":"Int J Urol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pros.24134","article-title":"Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy","volume":"81","author":"Qu","year":"2021","unstructured":"Qu F, Gu Y, Xue M, He M, Zhou F, Wang G and Peng Y. Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy. Prostate 2021; 81: 560-571.","journal-title":"Prostate"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1245\/s10434-018-7035-z","article-title":"Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status","volume":"26","author":"McClintock","year":"2019","unstructured":"McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, Fletcher SA, Roghmann F, Menon M, Nguyen PL, Noldus J, Choueiri TK, Kibel AS and Trinh QD. Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status. Ann Surg Oncol 2019; 26: 297-305.","journal-title":"Ann Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/biom11040492","article-title":"Current status and future perspectives of androgen receptor inhibition therapy for prostate cancer: a comprehensive review","volume":"11","author":"TJ","year":"2021","unstructured":"Kim TJ, Lee YH and Koo KC. Current status and future perspectives of androgen receptor inhibition therapy for prostate cancer: a comprehensive review. Biomolecules 2021; 11: 492.","journal-title":"Biomolecules"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1007\/s10147-021-01942-8","article-title":"Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy","volume":"26","author":"Matsumoto","year":"2021","unstructured":"Matsumoto K, Niwa N, Kosaka T, Takeda T, Yasumizu Y, Tanaka N, Morita S, Mizuno R, Shinojima T, Asanuma H and Oya M. Negative impact of neoadjuvant hormonal therapy on detecting biochemical recurrence after radical prostatectomy. Int J Clin Oncol 2021; 26: 1722-1728.","journal-title":"Int J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/JU.0000000000003876","article-title":"A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy","volume":"211","author":"Qian","year":"2024","unstructured":"Qian H, Chi C, Tricard T, Zhu Y, Dong L, Wang Y, Sha J, Wang J, Ma Z, Wang Y, Liu J, Dong B, Pan J and Xue W. A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy. J Urol 2024; 211: 648-655.","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.urology.2013.06.062","article-title":"Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality\/hormonal and sexual quality of life: results of a multicenter prospective study","volume":"82","author":"HA","year":"2013","unstructured":"Gay HA, Michalski JM, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal C, Litwin M, Kuban D, Hembroff L, Chang P and Sanda MG; PROSTQA Consortium. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality\/hormonal and sexual quality of life: results of a multicenter prospective study. Urology 2013; 82: 1363-1368.","journal-title":"Urology"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Nelson DR, Brown J, Morikawa A and Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS One 2022; 17: e0264637.","DOI":"10.1371\/journal.pone.0264637"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"673021","DOI":"10.1155\/2011\/673021","article-title":"Frequency of positive surgical margin at prostatectomy and its effect on patient outcome","volume":"2011","author":"Iczkowski","year":"2011","unstructured":"Iczkowski KA and Lucia MS. Frequency of positive surgical margin at prostatectomy and its effect on patient outcome. Prostate Cancer 2011; 2011: 673021.","journal-title":"Prostate Cancer"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Huang MM, Rac G, Felice M, Ellis JL, Handa N, Li EV, McCormick M, Bsatee A, Piyevsky B, Ross AE, Yonover PM, Gupta GN and Patel HD. Prostate magnetic resonance imaging to predict grade concordance, extra prostatic extension, and biochemical recurrence after radical prostatectomy. Urol Oncol 2025; 43: 445.e411-445.e419.","DOI":"10.1016\/j.urolonc.2025.02.013"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/jamasurg.2015.1704","article-title":"Effect of relative decrease in blood hemoglobin concentrations on postoperative morbidity in patients who undergo major gastrointestinal surgery","volume":"150","author":"Spolverato","year":"2015","unstructured":"Spolverato G, Kim Y, Ejaz A, Frank SM and Pawlik TM. Effect of relative decrease in blood hemoglobin concentrations on postoperative morbidity in patients who undergo major gastrointestinal surgery. JAMA Surg 2015; 150: 949-956.","journal-title":"JAMA Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13014-022-02046-x","article-title":"Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer","volume":"17","author":"Tsumura","year":"2022","unstructured":"Tsumura H, Tanaka N, Oguchi T, Owari T, Nakai Y, Asakawa I, Iijima K, Kato H, Hashida I, Tabata KI, Satoh T and Ishiyama H. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol 2022; 17: 71.","journal-title":"Radiat Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00345-024-05412-4","article-title":"Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial","volume":"43","author":"Zhang","year":"2025","unstructured":"Zhang X, Zhou F, Lu T, Zhang S, Wei X, Qiu X, Xu L, Guo H and Zhuang J. Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial. World J Urol 2025; 43: 58.","journal-title":"World J Urol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-10-2804","article-title":"Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients","volume":"17","author":"Sorrentino","year":"2011","unstructured":"Sorrentino C, Musiani P, Pompa P, Cipollone G and Di Carlo E. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin Cancer Res 2011; 17: 1571-1581.","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wang H, Li N, Liu Q, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang X, Yu Z, Jiang J, Huang H and Qin J. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 2023; 41: 1345-1362, e1349.","DOI":"10.1016\/j.ccell.2023.05.016"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/1878-0261.12327","article-title":"Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration","volume":"12","author":"Cioni","year":"2018","unstructured":"Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, Wessels LFA, Zwart W and Bergman AM. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration. Mol Oncol 2018; 12: 1308-1323.","journal-title":"Mol Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/pcan.2014.30","article-title":"Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy","volume":"17","author":"Stewart","year":"2014","unstructured":"Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, Gettman MT, Tollefson MK, Umbriet EC, Psutka SP, Bergstralh EJ, Rangel L and Karnes RJ. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis 2014; 17: 332-337.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.eururo.2021.03.009","article-title":"Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy","volume":"80","author":"Wilkinson","year":"2021","unstructured":"Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, Madan RA, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL and Sowalsky AG. Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy. Eur Urol 2021; 80: 746-757.","journal-title":"Eur Urol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ijc.31346","article-title":"Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer","volume":"143","author":"Cui","year":"2018","unstructured":"Cui J, Wang Y, Dong B, Qin L, Wang C, Zhou P, Wang X, Xu H, Xue W, Fang YX and Gao WQ. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer. Int J Cancer 2018; 143: 645-656.","journal-title":"Int J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S0022-5347(05)00165-5","article-title":"Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits","volume":"175","author":"Candas","year":"2006","unstructured":"Candas B, Labrie F, Gomez JL, Cusan L, Chevrette E, Lévesque J and Brousseau G. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol 2006; 175: 510-516.","journal-title":"J Urol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1210\/mend.12.7.0136","article-title":"Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest","volume":"12","author":"JM","year":"1998","unstructured":"Kokontis JM, Hay N and Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998; 12: 941-953.","journal-title":"Mol Endocrinol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","unstructured":"Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A and Calvo FA. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16: 320-327.","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"20503121221142171","DOI":"10.1177\/20503121221142171","article-title":"Overall 5-year survival rate and disease-free survival after segmentectomy versus lobectomy in patients with non-small cell lung cancer","volume":"10","author":"Kadeetham","year":"2022","unstructured":"Kadeetham K, Ngodngamthaweesuk M, Kantathut N, Samankatiwat P, Cherntanomwong P, Leelayana P and Khajarern S. Overall 5-year survival rate and disease-free survival after segmentectomy versus lobectomy in patients with non-small cell lung cancer. SAGE Open Med 2022; 10: 20503121221142171.","journal-title":"SAGE Open Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41571-019-0284-3","article-title":"Cytoreductive treatment strategies for de novo metastatic prostate cancer","volume":"17","author":"Connor","year":"2020","unstructured":"Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M and Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol 2020; 17: 168-182.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/EDBK_237987","article-title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies","volume":"39","author":"Datta","year":"2019","unstructured":"Datta M, Coussens LM, Nishikawa H, Hodi FS and Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book 2019; 39: 165-174.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/bju.14369","article-title":"Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems","volume":"122","author":"Pompe","year":"2018","unstructured":"Pompe RS, Beyer B, Haese A, Preisser F, Michl U, Steuber T, Graefen M, Huland H, Karakiewicz PI and Tilki D. Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU Int 2018; 122: 801-807.","journal-title":"BJU Int"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3171\/2012.2.PEDS11497","article-title":"Complications of occipital screw placement for occipitocervical fusion in children","volume":"9","author":"Hwang","year":"2012","unstructured":"Hwang SW, Gressot LV, Chern JJ, Relyea K and Jea A. Complications of occipital screw placement for occipitocervical fusion in children. J Neurosurg Pediatr 2012; 9: 586-593.","journal-title":"J Neurosurg Pediatr"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.urology.2010.05.013","article-title":"Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer","volume":"77","author":"Kattan","year":"2011","unstructured":"Kattan MW, Yu C, Salomon L, Vora K, Touijer K and Guillonneau B. Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer. Urology 2011; 77: 396-401.","journal-title":"Urology"}],"container-title":["American Journal of Translational Research"],"original-title":[],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:41:18Z","timestamp":1792658478000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/12\/ajtr0167227.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/fewg4694","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}